Company Information

CIN
Status
Date of Incorporation
22 January 2014
State / ROC
Pune / ROC Pune
Last Balance Sheet
31 March 2021
Last Annual Meeting
27 November 2021
Paid Up Capital
500,000
Authorised Capital
500,000

Directors

Anandibai Chandrakant Jagtap
Anandibai Chandrakant Jagtap
Director
about 2 years ago
Sanjay Chandrakant Jagtap
Sanjay Chandrakant Jagtap
Beneficial Owner
over 2 years ago
Mahadeo Sahebrao Jadhav
Mahadeo Sahebrao Jadhav
Director
almost 12 years ago

Patents

Alpha Tea Salt Forms: Compositions And Uses For Treating Disease

The present disclosure relates to salts of the compound (I) polymorphic forms thereof methods for preparation and use thereof and pharmaceutical compositions thereof.

Attenuated Chikungunya Virus

Novel attenuating deletions of Chikungunya virus E2 polypeptides are provided as are attenuated viruses comprising the deletions. Also provided are immunogenic compositions comprising the attenuated viruses and methods of producing such viruses in cells (such as insect cells). Viruses of the embodiments can be used ...

Flavivirus Host Range Mutations And Uses Thereof

Methods and compositions concerning mutant flaviviruses with host range mutations. In some embodiments the invention concerns nucleotide sequences that encode mutant flavivirus proteins. Viruses comprising these sequences that display reduced replication in mammalian cells are provided. In further aspects of the inv...

"Blys Fusion Proteins For Targeting Blys Receptor And Methods For Treatment Of B Cell Proliferative Disorders"

The present invention regards targeted BLyS polypeptides capable of binding to BLyS receptors and that deliver a cytotoxic agent, such as a cytotoxic peptide, for example. In particular aspects, the cytotoxic agent comprises at least part of rGelonin. These compositions are useful for treating, preventing, and/...

"Targeted Chimeric Molecules For Cancer Therapy"

The present invention concerns chimeric cancer therapeutic molecules comprising a targeting rnoiety and an anti-cell proliferation moiety. The anti-cell proliferation moiety may comprise a cytotoxic agent or an apoptosis-inducing factor, in specific embodiments. In particular embodiments, the anti-cell proliferation...

Documents

Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-07112020
Directors report as per section 134(3)-07112020
Optional Attachment-(1)-07112020
Form AOC-4-07112020_signed
Form BEN - 2-13102020_signed
Declaration under section 90-13102020
List of share holders, debenture holders;-22092020
Form MGT-7-22092020_signed
Form MGT-7-11032019_signed
Form AOC-4-11032019_signed
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-05032019
Directors report as per section 134(3)-05032019
List of share holders, debenture holders;-05032019
Directors report as per section 134(3)-26112017
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-26112017
List of share holders, debenture holders;-26112017
Form AOC-4-26112017_signed
Form MGT-7-26112017_signed
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-19012017
Directors report as per section 134(3)-19012017
Form AOC-4-19012017_signed
Form MGT-7-05122016_signed
Optional Attachment-(1)-29112016
List of share holders, debenture holders;-29112016
Form MGT-7-280116.OCT
Form AOC-4-020116.OCT
Form ADT-1-311015.OCT
Form MGT-14-260515.OCT
Copy of resolution-260515.PDF
Form23AC-220115 for the FY ending on-310314.OCT